Close
  Indian J Med Microbiol
 

Figure 1: Cumulative incidences of endometrial cancer in nonusers, tamoxifen-only users, and sequenced AI users. (a) all patients; the 14-year incidence in nonusers, tamoxifen-only users, and sequenced AI users was 0.3%, 1.7%, and 1.3%, respectively, (b) <50 years old; the 14-year incidence in nonusers, tamoxifen-only users, and sequenced AI users was 0.2%, 1.4%, and 0.2%, respectively, and (c) =50 years old; the 14-year incidence in nonusers, tamoxifen-only users, and sequenced AI users was 0.6%, 2.3%, and 2.0%, respectively, (Kaplan–Meier method). AI: Aromatase inhibitor

Figure 1: Cumulative incidences of endometrial cancer in nonusers, tamoxifen-only users, and sequenced AI users. (a) all patients; the 14-year incidence in nonusers, tamoxifen-only users, and sequenced AI users was 0.3%, 1.7%, and 1.3%, respectively, (b) <50 years old; the 14-year incidence in nonusers, tamoxifen-only users, and sequenced AI users was 0.2%, 1.4%, and 0.2%, respectively, and (c) =50 years old; the 14-year incidence in nonusers, tamoxifen-only users, and sequenced AI users was 0.6%, 2.3%, and 2.0%, respectively, (Kaplan–Meier method). AI: Aromatase inhibitor